Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03057106
Title Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Canadian Cancer Trials Group
Indications

lung non-small cell carcinoma

Therapies

Cisplatin

Gemcitabine

Carboplatin

Durvalumab + Tremelimumab

Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries CAN

Additional content available in CKB BOOST